Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats relapsing forms of multiple sclerosis (MS). Sold as Vumerity. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 22, 2026, FDA lists 2 applications for Diroximel fumarate (sold as Vumerity), first approved Oct 29, 2019, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Vumerity
$71.7M for 7,476 prescriptions, +3% on 2024
Where Medicare prescribes it
21,006 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Michigan 1.7×, New Jersey 1.4×, Virginia 1.4×
Least
California 0.8×, Florida 0.9×, Texas 1.0×
How its trials ended
9 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Ongoing444%OngoingCount4Share44%
Completed, result not reported333%Completed, result not reportedCount3Share33%
Stopped: sponsor or business decision222%Stopped: sponsor or business decisionCount2Share22%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA